NCT03233204: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, ATM, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patient must have enrolled on the Pediatric MATCH Screening Trial (NCT03155620)
Exclusions: Patients over the age of 21; Patients who have received prior exposure to PARP inhibitors (e.g. olaparib, veliparib, niraparib, rucaparib, talazoparib); Patients with symptomatic or uncontrolled central nervous system (CNS) metastases- see trial for details 
https://ClinicalTrials.gov/show/NCT03233204

Comments are closed.

Up ↑